Global Artificial Valve Market Size By Type (Transcatheter Valve, Tissue Valve), By Application (Below 20 Years Old, 20-30 Years Old), By Region, And Segment Forecasts, 2023 to 2032

The Global Artificial Valve Market was valued at USD 8.2 billion in 2023 and is projected to surpass USD 14.6 billion by 2031, growing at a CAGR of 7.2% during the forecast period (2023-2031). The increasing prevalence of cardiovascular diseases (CVDs), technological advancements in artificial heart valves, and the rising demand for minimally invasive surgeries are key factors driving market growth. Artificial valves are essential in treating heart valve diseases, offering life-saving solutions to patients with valvular disorders. The growing elderly population and increasing awareness about heart valve replacement procedures further contribute to market expansion.

Market Dynamics

Drivers

Rising Prevalence of Cardiovascular Diseases (CVDs)

The increasing incidence of heart valve diseases, including aortic stenosis and mitral regurgitation, is a primary driver of market growth.

According to the World Health Organization (WHO), CVDs are the leading cause of death globally, accounting for nearly 17.9 million deaths annually.

Technological Advancements in Artificial Valve Design

Innovations such as transcatheter aortic valve replacement (TAVR), bioprosthetic valves, and polymer-based valves are improving patient outcomes.

The introduction of 3D printing technology in artificial valve manufacturing is enhancing customization and precision.

Growing Demand for Minimally Invasive Surgeries (MIS)

Minimally invasive heart valve replacement procedures reduce hospital stays, lower infection risks, and promote faster recovery.

The increasing preference for transcatheter valve replacement procedures over traditional open-heart surgeries is boosting market demand.

Restraints

High Cost of Artificial Valves and Surgery

The cost of artificial valve replacement procedures, including TAVR and surgical valve replacements, remains high, limiting accessibility in low-income regions.

Stringent Regulatory Approvals

The regulatory approval process for artificial valves is highly stringent, requiring extensive clinical trials to ensure safety and efficacy.

Regulatory hurdles often delay the commercialization of new and advanced valve technologies.

Opportunities

Growing Adoption of Bioprosthetic and Next-Gen Polymer Valves

Increasing preference for bioprosthetic valves over mechanical valves due to reduced risk of blood clot formation is a key opportunity for manufacturers.

The emergence of polymer-based artificial valves, which offer durability and better biocompatibility, is expected to drive future growth.

Expanding Market in Emerging Economies

Developing healthcare infrastructure and rising medical tourism in Asia-Pacific, Latin America, and the Middle East & Africa present significant growth opportunities.

Government initiatives aimed at increasing access to advanced cardiovascular treatments are propelling market expansion.

Increasing Research & Development (R&D) in Personalized Medicine

The rise of patient-specific artificial valves using AI-driven diagnostic tools and 3D-printed heart valves is a promising avenue for market players.

Market Segmentation

Market by Valve Type Insights

Transcatheter Aortic Valve Replacement (TAVR)

This segment is expected to hold the largest market share due to its minimally invasive nature and rising adoption in high-risk patients.

Increasing FDA approvals for next-generation transcatheter heart valves are supporting market growth.

Mechanical Heart Valves

Preferred for younger patients due to durability but require lifelong anticoagulation therapy.

Continuous advancements in material science are improving mechanical valve designs.

Biological (Tissue) Heart Valves

Growing adoption of bovine and porcine tissue valves due to their reduced need for anticoagulation therapy.

Research on decellularized and regenerative heart valves is gaining traction.

Market by End-Use Insights

Hospitals

Hospitals remain the largest revenue contributor, accounting for over 60% of the market share in 2023.

The availability of advanced surgical infrastructure and specialized cardiology departments boosts the adoption of artificial valves.

Ambulatory Surgical Centers (ASCs)

Increasing preference for outpatient and minimally invasive valve replacement procedures is driving growth in ASCs.

Cardiac Research Centers

Growing focus on R&D for next-generation valve technologies is supporting demand from research institutions.

Regional Insights

North America

Dominated the global market in 2023, driven by advanced healthcare infrastructure, high adoption of innovative valve technologies, and increasing prevalence of CVDs.

The U.S. leads the market due to favorable reimbursement policies and a strong presence of key market players.

Europe

Europe holds a significant market share, supported by the high adoption of minimally invasive heart valve procedures.

Countries such as Germany, the U.K., and France are key contributors to market growth.

Asia-Pacific

Expected to be the fastest-growing region during the forecast period, fueled by improving healthcare access, rising medical tourism, and increasing government investments in cardiac care.

China, India, and Japan are emerging as key growth markets.

Latin America & Middle East & Africa (MEA)

Increasing awareness about artificial valve replacement procedures and improving healthcare infrastructure in Brazil, Mexico, South Africa, and UAE are creating growth opportunities.

Competitive Scenario

Key players in the Global Artificial Valve Market include:

Edwards Lifesciences Corporation

Medtronic plc

Abbott Laboratories

Boston Scientific Corporation

LivaNova PLC

CryoLife, Inc.

Braile Biomédica

Micro Interventional Devices, Inc.

JenaValve Technology, Inc.

Recent Market Developments

2023: Medtronic launched a next-generation transcatheter heart valve system, enhancing durability and hemodynamic performance.

2023: Edwards Lifesciences received FDA approval for its latest self-expanding transcatheter aortic valve replacement (TAVR) system.

2022: Abbott introduced a new bioprosthetic mitral valve, improving patient outcomes for mitral valve disease.

Scope of Work – Global Artificial Valve Market